Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice

Nature Medicine

Volumn 10, Issue 6, 2004, Pages 602-609

  Eichhorst, Sören T ^a   Krueger, Andreas ^b   Müerköster, Susanne ^c   Fas, Stefanie C ^d   Golks, Alexander ^d   Gruetzners, Uwe ^a   Schubert, Louise ^a   Opelz, Christine ^a   Bilzer, Manfred ^a   Gerbes, Alexander L ^a   Krammer, Peter H ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CASPASE 10; CASPASE 8; CASPASE 9; DEATH RECEPTOR 5; FAS ANTIGEN; GROWTH FACTOR; SURAMIN; TUMOR NECROSIS FACTOR; UREA DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; LIVER TRANSPLANTATION; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE; DEXAMETHASONE; ENZYME ACTIVATION; GAMMA RAYS; HUMANS; IN SITU NICK-END LABELING; LIVER; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, TUMOR NECROSIS FACTOR; SURAMIN; TRYPANOCIDAL AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 2942729545     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1049     Document Type: Article

References (39)

1. Krammer, P.H., Galle, P.R., Moller, P. & Debatin, K.M. CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv. Cancer Res. 75, 251-273 (1998).
2. Krammer, P.H. CB95(APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 71, 163-210 (1999).
3. Galle, P.R. et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182, 1223-1230 (1995).
4. Voogd, T.E., Vansterkenburg, E.L., Wilting, J. & Janssen, L.H. Recent research on the biological activity of suramin. Pharmacol. Rev. 45, 177-203 (1993).
5. Mitsuya, H. et al. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226, 172-174 (1984).
6. Yarchoan, R. & Broder, S. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N. Engl. J. Med. 316, 557-564 (1987).
7. Cheson, B.D. et al. Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. J. Am. Med. Assoc. 258, 1347-1351 (1987).
8. Allolio, B. et al. Treatment of metastatic adrenal carcinoma with suramin. Dtsch. Med. Wochenschr. 114, 381-384 (1989).
9. La Rocca, R.V., Stein, C.A. & Myers, C.E. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells 2, 106-115 (1990).
10. Eisenberger, M.A. & Reyno, L.M. Suramin. Cancer Treat. Rev. 20, 259-273 (1994).
11. Krueger, A., Schmitz, I., Baumann, S., Krammer, P.H. & Kirchhoff, S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276, 20633-20640 (2001).
12. Muller, M. et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188, 2033-2045 (1998).
13. Eichhorst, S.T., Muerkoster, S., Weigand, M.A. & Krammer, P.H. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res. 61, 243-248 (2001).
14. Collette, Y., Razanajaona, D., Ghiotto, M. & Olive, D. CD28 can promote T cell survival through a phosphatidylinositol 3-kinase-independent mechanism. Eur. J. Immunol. 27, 3283-3289 (1997).
15. Scaffidi, C. et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687 (1998).
16. Rokhlin, O.W. et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 57, 1758-1768 (1997).
17. Troy, C.M. & Shelanski, M.L. Caspase-2 redux. Cell Death Differ. 10, 101-107 (2003).
18. Sprick, M.R. et al. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 21, 4520-4530 (2002).
19. Ogasawara, J. et al. Lethal effect of the anti-Fas antibody in mice. Nature 364, 806-809 (1993).
20. Jaeschke, H. et al. Activation of caspase 3 (CPP32)-like proteases is essential for TNF-α-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J. Immunol. 160, 3480-3486 (1998).
21. Peterlin, B.M. & Trono, D. Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat. Rev. Immunol. 3, 97-107 (2003).
22. Kuyu, H., Lee, W.R., Bare, R., Hall, M.C. & Torti, F.M. Recent advances in the treatment of prostate cancer. Ann. Oncol. 10, 891-898 (1999).
23. Small, E.J. et al. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J. Clin. Oncol. 20, 3369-3375 (2002).
24. Song, S., Wientjes, M.G., Gan, Y. & Au, J.L. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc. Natl. Acad. Sci. USA 97, 8658-8663 (2000).
25. + T cells by fibroblast growth factor-1 (acidic fibroblast growth factor). J. Immunol. 155, 3904-3911 (1995).
26. Higuchi, H. et al. Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. J. Biol. Chem. 278, 454-461 (2003).
27. Reinehr, R., Graf, D., Fischer, R., Schliess, F. & Haussinger, D. Hyperosmolarity triggers CD95 membrane trafficking and sensitizes rat hepatocytes toward CD95L-induced apoptosis. Hepatology36, 602-614 (2002).
28. 2 purinoceptor in renal mesangial cells. Br. J. Pharmacol. 136, 520-529 (2002).
29. Lambrecht, G. et al. Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptor antagonists. Curr. Pharm. Des. 8, 2371-2399 (2002).
30. Kharlamov, A., Jones, S.C. & Kim, D.K. Suramin reduces infarct volume in a model of focal brain ischemia in rats. Exp. Brain Res. 147, 353-359 (2002).
31. Chen, E.Y., Mazure, N.M., Cooper, J.A. & Giaccia, A.J. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 61, 2429-2433 (2001).
32. 14C]suramin in tissues of male rats following a single intravenous dose. Life Sci. 67, 1847-1857 (2000).
33. Scaffidi, C., Medema, J.P., Krammer, P.H. & Peter, M.E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 272, 26953-26958 (1997).
34. Scaffidi, C., Krammer, P.H. & Peter, M.E. Isolation and analysis of components of CD95 (APO-1/Fas) death-inducing signaling complex. Methods 17, 287-291 (1999).
35. Trauth, B.C. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305 (1989).
36. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157-163 (1999).
37. Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F. & Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139, 271-279 (1991).
38. Kischkel, F.C. et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588 (1995).
39. Medema, J.P. et al. Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur. J. Immunol. 27, 3492-3498 (1997).